C9orf72 and amyotrophic lateral sclerosis: Their concentration in blood may also be informative as pharmacodynamic biomarker in clinical trials where faster progressing ALS and individuals with the C9orf72 genetic mutation (C9+ve ALS) have been recently singled out for their response to high‐caloric diet and gene‐modifying treatments.15